TWI722576B - 用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途 - Google Patents

用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途 Download PDF

Info

Publication number
TWI722576B
TWI722576B TW108133859A TW108133859A TWI722576B TW I722576 B TWI722576 B TW I722576B TW 108133859 A TW108133859 A TW 108133859A TW 108133859 A TW108133859 A TW 108133859A TW I722576 B TWI722576 B TW I722576B
Authority
TW
Taiwan
Prior art keywords
polypeptide
mhc
cases
type
multimeric
Prior art date
Application number
TW108133859A
Other languages
English (en)
Chinese (zh)
Other versions
TW201946933A (zh
Inventor
羅納德 西德爾三世
羅多弗 加帕洛
布蘭登 席勒瑞奇
史考特 加佛士
史蒂芬 艾爾莫
Original Assignee
耶奇華大學艾柏特艾因斯坦醫學院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 耶奇華大學艾柏特艾因斯坦醫學院 filed Critical 耶奇華大學艾柏特艾因斯坦醫學院
Publication of TW201946933A publication Critical patent/TW201946933A/zh
Application granted granted Critical
Publication of TWI722576B publication Critical patent/TWI722576B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW108133859A 2014-06-18 2015-06-17 用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途 TWI722576B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462013715P 2014-06-18 2014-06-18
US62/013,715 2014-06-18
PCT/US2015/035777 WO2015195531A2 (en) 2014-06-18 2015-06-15 Syntac polypeptides and uses thereof
WOPCT/US15/35777 2015-06-15

Publications (2)

Publication Number Publication Date
TW201946933A TW201946933A (zh) 2019-12-16
TWI722576B true TWI722576B (zh) 2021-03-21

Family

ID=54936224

Family Applications (3)

Application Number Title Priority Date Filing Date
TW108133859A TWI722576B (zh) 2014-06-18 2015-06-17 用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途
TW110108178A TWI795740B (zh) 2014-06-18 2015-06-17 用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途
TW104119612A TWI696633B (zh) 2014-06-18 2015-06-17 用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW110108178A TWI795740B (zh) 2014-06-18 2015-06-17 用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途
TW104119612A TWI696633B (zh) 2014-06-18 2015-06-17 用於Ｔ細胞活化之突觸（ｓｙｎＴａｃ）多肽類及彼等之用途

Country Status (15)

Country Link
US (6) US20170058015A1 (enExample)
EP (3) EP3157552B1 (enExample)
JP (4) JP6652932B2 (enExample)
KR (1) KR102252119B1 (enExample)
CN (3) CN113248624B (enExample)
AU (3) AU2015277460B2 (enExample)
DK (2) DK3480213T3 (enExample)
ES (2) ES2767259T3 (enExample)
HU (2) HUE047255T2 (enExample)
IL (3) IL248979B (enExample)
PL (2) PL3480213T3 (enExample)
PT (2) PT3157552T (enExample)
SG (2) SG10202006338UA (enExample)
TW (3) TWI722576B (enExample)
WO (1) WO2015195531A2 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201504558TA (en) 2012-12-11 2015-07-30 Einstein Coll Med Methods for high throughput receptor:ligand identification
CA3014458A1 (en) * 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2017151940A2 (en) * 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
SG11201808552XA (en) * 2016-05-18 2018-10-30 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
IL262606B2 (en) * 2016-05-18 2023-04-01 Albert Einstein College Medicine Inc pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
CN118085109A (zh) * 2016-08-11 2024-05-28 昆士兰医学研究所理事会 免疫调节化合物
CN110325205B (zh) * 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
US11407806B2 (en) 2017-04-06 2022-08-09 Albert Einstein College Of Medicine Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells
CN110869494B (zh) * 2017-06-12 2025-02-18 西奈卫生系统公司 无需全身性免疫遏制的同种异体移植物耐受
CN107266581B (zh) * 2017-06-13 2021-07-09 四川大学 藏猪il-12重组质粒增强pcv2疫苗免疫佐剂的制备方法及应用
BR112020002636A2 (pt) * 2017-08-10 2020-07-28 Grifols Diagnostic Solutions Inc. composições, métodos e/ou kits que compreendem um domínio extracelular recombinante de cd38 humano
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
MX2020002596A (es) * 2017-09-07 2020-07-20 Cue Biopharma Inc Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos.
EP3678677A4 (en) * 2017-09-07 2021-06-16 Cue Biopharma, Inc. ANTIGEN-PRESENTING POLYPEPTIDES AND METHOD FOR THEIR USE
WO2019051126A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
KR20190065234A (ko) * 2017-11-30 2019-06-11 그리폴스 다이어그노스틱 솔루션즈 인크. 면역 관문 억제제인 pd-1 및 pd-l1에 대한 항체 치료를 모니터링하기 위한 면역분석 및 조작된 단백질
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4534560A3 (en) 2018-03-24 2025-06-11 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
WO2020056152A1 (en) * 2018-09-12 2020-03-19 Chang Liu Single chain constructs
CA3123102A1 (en) 2018-12-13 2020-06-18 Sinai Health System Immunomodulatory cells and uses thereof
EP3897690A4 (en) * 2018-12-19 2022-09-28 Cue Biopharma, Inc. T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP3897746A4 (en) * 2018-12-19 2022-10-26 Cue Biopharma, Inc. MULTIMERIC T LYMPHOCYTE MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
WO2020181062A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP7691927B2 (ja) * 2019-03-06 2025-06-12 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
KR20220015382A (ko) * 2019-05-29 2022-02-08 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
EP4028412A2 (en) * 2019-09-13 2022-07-20 The Regents of The University of California Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications
EP4030897A4 (en) * 2019-09-20 2023-10-18 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
WO2021081232A1 (en) * 2019-10-23 2021-04-29 Cue Biopharma, Inc. Modified cytotoxic t cells and methods of use thereof
CN114599674A (zh) * 2019-10-23 2022-06-07 库尔生物制药有限公司 T细胞调节嵌合分子及其使用方法
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
US20230076204A1 (en) * 2020-02-18 2023-03-09 Institute For Systems Biology Single chain trimer mhc class ii nucleic acids and proteins and methods of use
WO2021168388A1 (en) * 2020-02-21 2021-08-26 3T Biosciences, Inc. Yeast display libraries, associated compositions, and associated methods of use
WO2021178975A1 (en) * 2020-03-06 2021-09-10 Albert Einstein College Of Medicine A method to generate chimeric antigen receptor (car) t-cells (car-t cells) from pathogen-specific cytotoxic lymphocytes to enable the subsequent in vivo modulation of their functional activity
WO2021195108A1 (en) * 2020-03-24 2021-09-30 Cue Biopharma, Inc. T cell modulatory polypeptides and methods of use thereof
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
WO2021230638A1 (en) * 2020-05-12 2021-11-18 Lg Chem, Ltd. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN113429486A (zh) * 2020-06-19 2021-09-24 百奥赛图(北京)医药科技股份有限公司 基因修饰非人动物的构建方法及应用
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
WO2022056015A1 (en) * 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof
CN112852744A (zh) * 2021-01-27 2021-05-28 河南省华隆生物技术有限公司 一种nk滋养层细胞及其制备方法和应用
CN112725284A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk滋养层细胞及其应用
CN112779224A (zh) * 2021-01-27 2021-05-11 河南省华隆生物技术有限公司 一种表达细胞因子组合物的nk滋养层细胞及其制备方法和应用
CN112725273A (zh) * 2021-01-27 2021-04-30 河南省华隆生物技术有限公司 一种nk细胞及其制备方法和应用
CN117222421A (zh) * 2021-03-19 2023-12-12 Cue生物制药股份有限公司 T细胞调节多肽和其使用方法
CA3215077A1 (en) * 2021-04-07 2022-10-13 Thomas J. Malia Peptide-mhc-immunoglobulin multimers and methods of use thereof
WO2022236102A1 (en) * 2021-05-07 2022-11-10 Institute For Systems Biology Single chain trimer mhc class i nucleic acids and proteins and methods of use
CA3229369A1 (en) 2021-08-16 2023-02-23 Regeneron Pharmaceuticals, Inc. Novel il27 receptor agonists and methods of use thereof
US20240376464A1 (en) * 2021-08-20 2024-11-14 3T Biosciences, Inc. PEPTIDE-HLA-B*35 Libraries, Associated Compositions, and Associated Methods of Use
EP4460515A1 (en) * 2022-01-03 2024-11-13 Aarhus Universitet Proteinaceous compound for generating specific cytotoxic t-cell effect
US20250271443A1 (en) * 2022-04-21 2025-08-28 Institute For Systems Biology Soluble single-chain dimers from cleavable single chain trimers
CN117186199A (zh) * 2022-05-31 2023-12-08 厦门大学 β2-微球蛋白封闭肽、其药物组合物及用途
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2024059740A1 (en) * 2022-09-14 2024-03-21 Synthego Corporation Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof
EP4654982A1 (en) 2023-01-27 2025-12-03 Regeneron Pharmaceuticals, Inc. Modified rhabdovirus glycoproteins and uses thereof
IL322890A (en) 2023-02-28 2025-10-01 Regeneron Pharma Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
WO2025081106A2 (en) * 2023-10-12 2025-04-17 Vanderbilt University Nanobody vaccine compositions
WO2026050395A1 (en) * 2024-08-29 2026-03-05 Achelois Biopharma, Inc. Single-chain trimer pmhc-i antigen-presenting vesicles as preventative and therapeutic vaccines for cancer and infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
EP2336167B1 (en) * 2001-03-14 2019-05-29 Dako Denmark A/S MHC molecule constructs and their uses for diagnosis and therapy
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2644712C (en) 2006-03-06 2016-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
US8518697B2 (en) * 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
EP2155782A2 (en) * 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
DK3178835T3 (da) * 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
HK1211949A1 (en) * 2012-11-30 2016-06-03 罗切格利卡特公司 Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
WO2019051127A1 (en) * 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
WO2019139896A1 (en) * 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring

Also Published As

Publication number Publication date
PL3480213T3 (pl) 2020-05-18
CA2947489A1 (en) 2015-12-23
KR20170030484A (ko) 2017-03-17
PT3480213T (pt) 2020-02-04
HUE047255T2 (hu) 2020-04-28
ES2767259T3 (es) 2020-06-17
TWI696633B (zh) 2020-06-21
TW201613966A (en) 2016-04-16
KR102252119B1 (ko) 2021-05-17
TWI795740B (zh) 2023-03-11
EP3480213A1 (en) 2019-05-08
AU2021204594A1 (en) 2021-07-29
WO2015195531A3 (en) 2016-02-25
TW202124435A (zh) 2021-07-01
CN113248623A (zh) 2021-08-13
EP3483179B1 (en) 2020-09-16
IL248979B (en) 2020-06-30
EP3157552B1 (en) 2019-10-23
AU2015277460B2 (en) 2020-10-08
IL266570A (en) 2019-07-31
SG11201609876TA (en) 2017-01-27
US20170058015A1 (en) 2017-03-02
JP6652932B2 (ja) 2020-02-26
AU2019203442A1 (en) 2019-06-06
AU2015277460A1 (en) 2016-11-24
JP6995151B2 (ja) 2022-02-21
DK3480213T3 (da) 2020-02-17
BR112016027897A2 (pt) 2017-10-24
US20210238254A1 (en) 2021-08-05
JP6652680B2 (ja) 2020-02-26
EP3157552A2 (en) 2017-04-26
JP2022046544A (ja) 2022-03-23
JP2020022491A (ja) 2020-02-13
WO2015195531A2 (en) 2015-12-23
JP7331075B2 (ja) 2023-08-22
SG10202006338UA (en) 2020-08-28
IL266570B (en) 2020-06-30
CN113248624A (zh) 2021-08-13
PT3157552T (pt) 2020-01-22
AU2021204594B2 (en) 2024-05-09
EP3157552A4 (en) 2017-11-22
US20210047384A1 (en) 2021-02-18
PL3157552T3 (pl) 2020-05-18
CN106456733B (zh) 2021-03-16
EP3483179A1 (en) 2019-05-15
JP2020072733A (ja) 2020-05-14
DK3157552T3 (da) 2020-01-13
AU2019203442B2 (en) 2021-04-08
JP2017519491A (ja) 2017-07-20
US20200377569A1 (en) 2020-12-03
TW201946933A (zh) 2019-12-16
EP3480213B1 (en) 2019-11-13
IL275307B (en) 2022-03-01
US20260109753A1 (en) 2026-04-23
IL275307A (en) 2020-07-30
CN106456733A (zh) 2017-02-22
CN113248624B (zh) 2025-02-07
ES2770330T3 (es) 2020-07-01
IL248979A0 (en) 2017-01-31
US20180282392A1 (en) 2018-10-04
HUE048076T2 (hu) 2020-07-28

Similar Documents

Publication Publication Date Title
JP7331075B2 (ja) ｓｙｎＴａｃポリペプチド及びその使用
CA2947489C (en) Syntac polypeptides and uses thereof
HK40005537A (en) Syntac polypeptides and uses thereof
HK40005537B (en) Syntac polypeptides and uses thereof
HK40005540A (en) Syntac polypeptides and uses thereof
HK40005540B (en) Syntac polypeptides and uses thereof
HK1234664B (zh) Syntac多肽及其用途
HK1234664A1 (en) Syntac polypeptides and uses thereof
BR112016027897B1 (pt) Polipeptídeo multimérico, proteína, método para modular seletivamente a atividade de uma célula t, composição e método para inibir seletivamente a atividade e/ou reduzir o número de uma célula t autorreativa
HK1236106A1 (en) Syntac polypeptides and uses thereof
HK1236106B (en) Syntac polypeptides and uses thereof